MTOR and cancer: The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway appears to be an attractive target for anticancer therapy due to the fact that, in majority of cancers, it is associated with aggressive phenotypes, chemoresistance, and poor prognosis [127].